This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
April 26, 2011 5:00 pm ET
Brian Smrdel – Chief Financial Officer
Stryker Warren, Jr. – Chief Executive Officer
Larry Haimovitch – HMTC
Ernest Andberg – Feltl & Company
Good day, ladies and gentlemen, and welcome to the Urologix Incorporated Fiscal 2011 Third Quarter Conference Call. My name is Ann and I will be your coordinator for today.
At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of the conference. As a reminder, this conference is being recorded for replay purposes.
Statements made at this presentation may contain forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in any forward-looking statements due to risks and uncertainties.
A detailed discussion of risks and uncertainties may be found in Urologix’s recent Annual Report on Form 10-K for the year ended June 30, 2010, and other documents filed with the Securities and Exchange Commission.
At this time, I will turn the call over to Mr. Stryker Warren, Jr., Chief Executive Officer. Please proceed, sir.
Stryker Warren, Jr.
Thank you, and good afternoon. This is Stryker Warren, and as Chief Executive Officer of Urologix, I welcome you to this earnings call to discuss the company’s results for the third quarter and fiscal year 2011. Joining me are Brian Smrdel, the company’s Chief Financial Officer; and Greg Fluet, the Executive Vice President and Chief Operating Officer of Urologix.